FHTX – foghorn therapeutics inc. (US:NASDAQ)

News

Foghorn Therapeutics (FHTX) was downgraded by Wall Street Zen from "b
Foghorn Therapeutics (FHTX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Foghorn Therapeutics (FHTX) had its "outperform" rating reaffirmed by Wedbush. They now have a $10.00 price target on the stock.
Foghorn Therapeutics GAAP EPS of -$1.18 misses by $0.08, revenue of $30.91M misses by $0.31M [Seeking Alpha]
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com